CCNE1 and breast cancer: In fact, cyclin E is frequently amplified in breast cancer, and cyclin E overexpression is associated with a poor clinical benefit of breast cancer, while inhibition of cyclin E-CDK2 activity dramatically reduces proliferation and tumor formation and considered as a therapeutic approach in cancer [8–12].